Bas Vandamme

Bas Vandamme currently serves as the Quality Asset Head for mRNA at Lonza, overseeing quality assurance for the mRNA business unit in Geleen since September 2022. Prior to this role, Bas held several positions at Lonza Netherlands, focusing on quality management for mRNA drug substances and therapies from January 2021 to September 2022. Experience also includes a role as a Qualified Person at Dechra Pharmaceuticals, where Bas led European market authorization for a generic drug and managed multiple quality assurance projects. Previous positions involved operational support for Sanofi Genzyme and quality consultancy roles at Q-People and eTheRNA Immunotherapies. Bas holds a Master of Science from both KU Leuven and University College Dublin, as well as a Bachelor of Science in Pharmaceutical Science from KU Leuven.